Botox REMS spurs Allergan's challenge to US off-label promotion rules
05 October 2009
Sue Sutter
Allergan is challenging US
FDA restrictions that prohibit it from disseminating information about off-label uses of Botox (onabotulinumtoxinA).
A lawsuit, filed in US District Court for the District of Columbia, seeks a preliminary injunction against enforcement of the off-label marketing restrictions...
Please Login to read the full article.
05 October 2009
Sue Sutter
A lawsuit, filed in US District Court for the District of Columbia, seeks a preliminary injunction against enforcement of the off-label marketing restrictions...
Please Login to read the full article.
RELATED CONTENT
NEWS
- US Capitol Capsule: Patent reform done, but will it create jobs?
- US Capitol Capsule: Stem cell researchers breathe sigh of relief on vacated injunction
- SMC recommends Napp's bendamustine in CLL, Genzyme's Renvela and . er, well . that's all
- Once, twice, three times approval for Botox but SMC frowns on Merz' cover
COMMENT
Other Informa Comment
EVENTS
26 February 2012
Vancouver Convention Centre | Vancouver, BC, Canada
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
